The sleep apnea devices market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%. The sleep apnea devices market is dominated by a few players globally. Players in this market compete with each other to deliver superior quality therapeutic and diagnostic products for OSA (Obstructive Sleep Apnea). In 2017, the sleep apnea devices market was dominated by a few large players, namely, ResMed, Inc. (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare Ltd. (New Zealand).
Product launches, product approvals, acquisitions, agreements, and contracts were the key strategies adopted by players between 2015 and 2018.
Download the PDF Brochure@ http://bit.ly/2QLPrQB
ResMed dominated the sleep apnea devices market in 2017. The company gained a major share in the sleep apnea devices market on account of its diversified product portfolio, widespread geographical presence, and focus on strategies such as innovation and expansions. The company strongly focuses on expansion into new product segments as well as geographies to gain a competitive edge in the market.
Thus, to enter the high growth market, ResMed acquired Laboratoires Narval, S.A. (France) to supply custom-made mandibular advancement devices. Additionally, in February 2016, ResMed acquired Brightree LLC (US), a provider of cloud-based software solutions for the post-acute care industry. This acquisition strengthened ResMed’s market position as well as significantly expanded its software product portfolio. ResMed also has a strong patent portfolio which helps the company maintain its leadering position in the market.
Koninklijke Philips is the second largest player in the global sleep apnea devices market. The company’s strong position in this market can be attributed to its acquisition of Respironics in 2008, a US-based established manufacturer and distributor of sleep and respiratory products. The company’s wide geographical presence and strong distribution network have also helped it to gain a significant market share.
In the past three years, innovation has been the company’s core business strategy to increase its share in the global sleep apnea devices market. This strategy is largely supported by the company’s strong R&D activities. The company invested USD 455.91 million (5.8% of its Personal Health segment sales) in R&D in 2017. The company’s rich pool of skilled R&D personnel ensures constant development and launch of technologically advanced products in the market. This further helps Philips to launch products like masks, PAP devices, and ventilators in the market.
Fisher & Paykel Healthcare accounted for the third largest share of the global sleep apnea devices market. The company strongly focuses on developing and establishing a direct sales force in major geographic markets. The company significantly invests in R&D activities to launch technologically advanced products in the market. The company’s rich pool of skilled R&D personnel ensures constant development and launch of advanced products in the market. It invested USD 59.94 million, USD 51.29 million, and USD 53.98 million in R&D in 2017, 2016, and 2015, respectively. As a result of its strong R&D activities, the company has launched sleep apnea products like nasal pillow masks, optiflow nasal cannulas, and Airspiral tubes. The growing workforce, strong R&D, and consistent new product launches are likely to help the company gain a greater market share in the coming years.
Read the Detailed Article on "Sleep Apnea Devices Market - Global Forecasts to 2023", Here..!
Other players in the sleep apnea devices market include SomnoMed Ltd. (Australia), Compumedics Limited (Australia), Löwenstein Medical GmbH & Co. KG. (Germany), Whole You, Inc. (US), BMC Medical Co., Ltd. (China), Drive DeVilbiss Healthcare (US), and Braebon Medical Corporation (Canada).
Target Audience:
- Medical devices manufacturing companies
- Medical devices suppliers and distributors
- Diagnostic laboratories
- Hospitals
- Venture capitalists
- Sleep laboratories
- Business research and consulting service providers
No comments:
Post a Comment